A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the performance and safety for the use of the investigational catheter for intracardiac mapping in the atria and ventricles.

Official Title
-----------------
Clinical Evaluation of Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter

Conditions
-----------------
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Ventricular Tachycardia, Premature Ventricular Complex

Intervention / Treatment
-----------------
* Device: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with and candidate for clinically-indicated catheter mapping and ablation procedure for the management of ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation (participants having undergone a previous ablation procedure may be included) At least one episode of the targeted arrhythmia (ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation) must have been documented by electrocardiogram (ECG), Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months of enrollment Signed participants Informed Consent Form (ICF) Able and willing to comply with all pre-, post-, and follow-up testing and requirements Exclusion Criteria: Diagnosed with an arrhythmia requiring epicardial mapping Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non-cardiac cause Atrial arrhythmias: participants with a left atrial size greater than (>) 55 millimeters (mm) Left Ventricular Ejection Fraction (LVEF) less than or equal to (<=) 25 percent (%) for participants with ventricular arrhythmia LVEF <= 40% for participants with atrial arrhythmia Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter Contraindication to anticoagulation (that is heparin, warfarin, dabigatran) History of blood clotting or bleeding abnormalities (example, hypercoagulable state) Myocardial infarction within the past 2 months (60 days) Documented thromboembolic event (including Transient Ischemic Attack [TIA]) within the past 12 months (365 days) Uncontrolled heart failure or New York Heart Association (NYHA) function class IV Implanted with a pacemaker or intracardiac cardiac defibrillator within the past 6 weeks (42 days) Participants with known untreatable allergy to contrast media Active illness or active systemic infection or sepsis Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) Any cardiac surgery within the past 60 days (2 months) (includes Percutaneous Coronary Intervention [PCI]) Atrial septal closure within the past 6 weeks (42 days) Presence of a condition that precludes vascular access Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being Concurrent enrollment in an investigational study evaluating another device or drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter<br>Participants with cardiac arrhythmias/ablation history who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for atrial and ventricular procedures will be using multi-electrode mapping catheter. | Device: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter<br>* Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Pre-ablation Mapping Performed Successfully with the Globe-Shaped, High-Density Multi-electrode Mapping Catheter Without Resort to Non-study Mapping Catheter | Number of participants with pre-ablation mapping performed successfully with the globe-shaped, high-density multi-electrode mapping catheter without resort to non-study mapping catheter will be reported. Pre-ablation mapping is considered complete when all of the following are accomplished, as applicable: 1) The entire chamber and areas associated with the targeted arrhythmia(s) are completely mapped using Fast Anatomical Mapping (FAM); 2) Substrate or previous lesion line associated with the arrhythmia(s) is mapped: a) Substrate Voltage mapping recommended for re-do Atrial Fibrillation (AF), Persistent Atrial Fibrillation (PsAF) and Ventricular Tachycardia (VT) procedures; b) Local activation mapping recommended for complex Atrial Tachycardia (AT) and VT procedures; 3) Conduction channel, gap(s) and critical isthmus are identified (as applicable); 4) Mapping density at the areas of interests (example slow conduction zones) is adequate, as assessed by the investigator. | For 1 day on the day of procedure (anytime during the study duration of 6 months) | 
| Number of Participants with Clinically Indicated Mapping Performed Successfully with the Globe-Shaped, High-Density Multi-electrode Mapping Catheter Without Resort to Non-study Mapping Catheter | Number of participants with clinically indicated mapping performed successfully with the globe-shaped, high-density multi-electrode mapping catheter without resort to non-study mapping catheter will be reported. | Up to 6 months | 
| Number of Participants with Serious Adverse Events (SAEs) within 7 days of Index Procedure Related to the Investigational Catheter | Number of participants with SAEs within 7 days of index procedure related to the investigational catheter will be reported. A serious adverse device effect is an adverse device effect that has resulted in any of the consequences characteristic of an SAE. A SAE is any event that meets one or more of the following criteria: a) leads to death; b) leads to a serious deterioration in the health of a participant that resulted in: i) life-threatening illness or injury; ii) an injury or permanent impairment of a body structure or a body function; iii) in-participant hospitalization or prolongation of an existing hospitalization; iv) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function; v) chronic disease; d) leads to fetal distress, fetal death or a congenital abnormality or birth defect. | Up to 7 days of index procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physician Assessment of Deployment, Maneuverability, and Signal Quality Acquired with the Globe-shaped, High-density Multi-electrode Mapping Catheter for Mapping in the Atria and Ventricles Using a Physician-completed Survey | Physician assessment of deployment, maneuverability, and signal quality acquired with the globe-shaped, high-density multi-electrode mapping catheter for mapping in the atria and ventricles using a physician-completed survey will be reported. A post-procedure survey of 11 questions, each with individual sub-questions will be administered. Each question/sub-question will be answered by the physician using a Likert scale of 1 to 7 (1=poor and 7=excellent) and will be summarized. | Up to 6 months | 
| Number of Participants with Other SAEs (Excluding Globe-shaped, High-density Multi-electrode Mapping Catheter Related SAE) within 7 days of Index Procedure | Number of Participants with other SAEs (excluding globe-shaped, high-density multi-electrode mapping catheter related SAE) within 7 days of index procedure will be reported. A serious adverse device effect is an adverse device effect that has resulted in any of the consequences characteristic of an SAE. A SAE is any event that meets one or more of the following criteria: a) leads to death; b) leads to a serious deterioration in the health of a participant that resulted in: i) life-threatening illness or injury; ii) an injury or permanent impairment of a body structure or a body function; iii) in-participant hospitalization or prolongation of an existing hospitalization; iv) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function; v) chronic disease; d) leads to fetal distress, fetal death or a congenital abnormality or birth defect. | Up to 7 days of index procedure | 
| Number of Participants with Non-serious Adverse Events within 7 days of Index Procedure Related to the Globe-shaped, High-density Multi-electrode Mapping Catheter | Number of participants with non-serious adverse events within 7 days of index procedure related to the globe-shaped, high-density multi-electrode mapping catheter will be reported. | Up to 7 days of index procedure |